Spero Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 0.00 shares.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 0.00 shares.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 0.00 shares.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 0.00 shares.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 56.12K shares, a 65.07% decline from fiscal 2021.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 160.67K shares, a 50.48% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-13 | 0.00 shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 0.00 shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 0.00 shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 0.00 shares derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-15 | 0.00 shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 0.00 shares 10-K · filed 2024-03-13 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 0.00 shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 0.00 shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-11 | 38.50K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 56.12K shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 81.22K shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 38.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 170.08K shares derived: sum of 4 quarters · filed 2022-08-10 |
| 2022-03-31 | 17.62K shares 10-Q · filed 2022-05-16 | 166.78K shares derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | 25.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 160.67K shares 10-K · filed 2022-03-31 |
| 2021-09-30 | 88.86K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 298.29K shares derived: sum of 4 quarters · filed 2021-11-10 |
| 2021-06-30 | 35.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 239.22K shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 11.51K shares 10-Q · filed 2021-05-06 | 244.55K shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 162.72K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | 324.43K shares 10-K · filed 2021-03-11 |
| 2020-09-30 | 29.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | |
| 2020-06-30 | 40.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | |
| 2020-03-31 | 91.40K shares 10-Q · filed 2020-05-08 | |
| 2019-12-31 | 78.61K shares 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |